Polyrizon Ltd. (PLRZ) Balance Sheet

The sharp decline in cash reserves over the latter half of 2025 suggests that the company's burn rate is significantly outpacing its ability to maintain a stable capital base. This trajectory implies that the firm is approaching a critical juncture where the current asset structure may no longer support ongoing R&D and regulatory compliance efforts.

While the current ratio appears high at 29.03, this metric is misleading due to the lack of meaningful current liabilities and the absence of revenue-generating operations. Investors should monitor the company's ability to secure non-dilutive funding, as the current cash runway appears insufficient to sustain the existing cost structure for more than a few quarters.

The minimal investment in PPE, reported at only $12,000, confirms an asset-light model that relies entirely on the intellectual property underlying the hydrogel platform. This structure places the entire valuation burden on the success of the R&D pipeline, as there are few tangible assets to provide a floor for recovery in a downside scenario.

The negative trend in retained earnings suggests that the company has yet to achieve a sustainable business model, forcing a reliance on equity financing that may lead to further dilution for existing shareholders. The quality of equity appears strained, as it is primarily a reflection of past capital raises rather than value created through operational success.